Acurx Pharmaceuticals, Inc. ("Acurx" or the "Company"), is a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections. It announced today ...

Portage la Prairie now has its first locally based infectious disease (ID) physician, as Dr. Zoe Muller began her practice in ...

Cabotegravir was already approved for use in England and Wales as part of a combination treatment for people living with HIV.

Researchers at La Jolla Institute for Immunology, Scripps Research, and the Ragon Institute of MGH, MIT, and Harvard report coordinated studies showing that several HIV germline-targeting immunogens ...

A recently approved twice-yearly injection to prevent HIV may warrant a higher price, but thousands of dollars more?  CVS Caremark’s chief medical officer calls on Gilead Sciences to lower the $28,000 ...

Patients with multidrug resistant HIV infection who switch to a single tablet of bictegravir/emtricitabine/tenofovir ...

It is believed the lenacapavir shot could end HIV/Aids in the country within 14 to 18 years if enough people were to take it.

There were still 32,000 new cases of HIV in the U.S. in 2022. And about thousands of people still die annually from AIDS. HIV ...

The rate of HIV infection continues to climb globally. Around 40 million people live with HIV-1, the most common HIV strain.

Oral HIV pre-exposure prophylaxis (PrEP) adoption varies across the US, with posters presented at the Academy of Managed Care Pharmacy Nexus 2025 meeting in National Harbor, Maryland, highlighting ...

Addressing the question of whether and how immune cells (macrophages) in the central nervous system (CNS) traffic out, ...